“This was a tremendous honor and I was completely star-struck, it was a humbling experience,” said Barker-Figueroa. “I don’t want the awards to be about me, I want it to be a conduit for education and bringing awareness to current Native American issues.”
“I’m so completely in love with the military, so [I thought] I’m gonna go there,” she said. “I was 21 and I arrived in Japan in February of ’47; the occupation was only a year and-a-half old.”
As a cost-effective alternative to both conventional and camelid single-domain antibodies for therapeutic, detection and biotechnology applications, recombinant production enables a more uniform and consistent product. Stabilizing high melting temperatures can greatly reduce the logistical cost of shipping and storing for detection, diagnostics and therapeutic reagents as they would no longer need to be maintained at refrigerated temperatures. This would lower development costs for new technologies focused on protecting the warfighter and civilian populations.
This new diagnostic device will allow quicker point-of-care testing of infected warfighters allowing for more rapid treatment and troop safety. After analytical comparisons with current CDC kits, the next step will be to gain ‘Emergency Use Authorization.’ This will accelerate the FDA development process, allowing the diagnostic tool to reach the warfighter sooner.